Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00066573 · OUTCOME

Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer · Source last updated 2023-08-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
5 years

What was measured

Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver.

Analysis population: Intent to treat

Groups in this outcome

Exemestane

Patients receive oral exemestane (25 mg) once daily for 5 years. exemestane: Given orally

Anastrozole

Patients receive oral anastrozole (1 mg) once daily for 5 years. anastrozole: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Exemestane3789
Anastrozole3787

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Exemestane157Not reportedNot reportedNot reportedNot reported
Anastrozole164Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        157
      2. group Id
        OG001
        value
        164
denoms
  1. counts
    1. group Id
      OG000
      value
      3789
    2. group Id
      OG001
      value
      3787
    units
    Participants
description
Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver.
groups
  1. description
    Patients receive oral exemestane (25 mg) once daily for 5 years. exemestane: Given orally
    id
    OG000
    title
    Exemestane
  2. description
    Patients receive oral anastrozole (1 mg) once daily for 5 years. anastrozole: Given orally
    id
    OG001
    title
    Anastrozole
param Type
COUNT_OF_PARTICIPANTS
population Description
Intent to treat
reporting Status
POSTED
time Frame
5 years
title
Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice